XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
PR Newswire —
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell...